APOE rs6733824: Understanding Promoter Variants and Brain Health
The rs6733824 variant is a genetic marker located in the promoter region of the APOE gene. Research suggests this non-coding variant may modulate APOE transcriptional activity, potentially influencing the risk of late-onset neurodegenerative conditions.
What each genotype means
Regulatory variant homozygous
This genotype represents two copies of the C allele at this regulatory site in the APOE promoter. Research indicates this variant modulates APOE transcriptional activity, which may influence lifetime risk of late-onset neurodegeneration, though the evidence remains limited and context-dependent.
Carried by approximately 25% of individuals based on a minor allele frequency of 0.45.
Regulatory variant heterozygous
This genotype represents one copy of the C allele and one copy of the T allele at this regulatory site. As a non-coding regulatory variant, it is associated with the modulation of APOE expression levels, which may contribute to variations in neurodegenerative risk profiles across different populations.
This is the most common genotype, carried by roughly 50% of individuals in many diverse continental ancestries.
Regulatory variant homozygous
This genotype represents two copies of the T allele at this regulatory site. While this variant is linked to the regulation of APOE activity, its specific contribution to neurodegenerative risk is considered limited and may be influenced by other genetic factors or ancestry-specific backgrounds.
Carried by approximately 25% of individuals based on a minor allele frequency of 0.45.
What is the rs6733824 Variant?
The rs6733824 variant is a single nucleotide polymorphism (SNP) situated within the promoter domain of the APOE gene. Unlike variants that change the structure of a protein, this SNP is located in a non-coding regulatory region. Promoter regions act as 'on-off' switches for genes, determining how much messenger RNA is produced from a specific DNA sequence. By residing in this regulatory area, rs6733824 is hypothesized to influence the transcriptional activity of the APOE gene, effectively modulating the amount of APOE protein synthesized by cells. Because APOE is a critical gene for lipid metabolism and brain health, variations in its expression levels are of significant interest to researchers studying the biological underpinnings of cognitive decline and neurodegeneration.
The Role of the APOE Gene
The APOE gene provides instructions for making apolipoprotein E, a protein that combines with fats in the body to form lipoproteins. These lipoproteins are responsible for packaging cholesterol and other fats and carrying them through the bloodstream. In the brain, APOE is the primary cholesterol carrier and plays a vital role in the maintenance and repair of neurons. It is also involved in the clearance of beta-amyloid, a protein fragment that can accumulate and form plaques in the brains of individuals with Alzheimer's disease. Because of these essential functions, the regulation of APOE expression is tightly controlled. Any genetic variation that alters this regulation, such as those in the promoter region, may impact the brain's ability to manage cholesterol and clear toxic protein aggregates.
Research and Evidence Strength
The association between APOE promoter variants and neurodegenerative risk is a subject of ongoing scientific investigation. While the APOE gene itself is well-established as a major risk factor for late-onset Alzheimer's disease, the specific contribution of promoter variants like rs6733824 is considered to have limited evidence strength. Some studies have suggested that promoter polymorphisms can influence APOE expression levels in laboratory settings, and researchers have explored whether these changes correlate with clinical outcomes. However, results in human populations have been mixed, and it remains difficult to isolate the effect of a single promoter SNP from the powerful influence of the well-known APOE coding alleles (such as e2, e3, and e4). Consequently, while this variant is a focus of academic study, it is not currently used as a definitive diagnostic tool for predicting individual health outcomes.
Population Frequency
The rs6733824 variant is relatively common, with a minor allele frequency of approximately 0.45 across diverse continental ancestries. This high frequency indicates that the variant is widely distributed throughout the global population, rather than being restricted to specific ethnic or geographic groups. Because it is so common, it is considered a standard part of human genetic variation. Researchers often account for this frequency when conducting large-scale genetic association studies to ensure that observed links to disease are not simply due to population structure or random chance.
Interpreting Your Genetic Information
It is important to understand that genetic variants like rs6733824 represent statistical associations observed in large groups, not individual medical predictions. The presence of a specific genotype does not guarantee that an individual will or will not develop a particular condition. Neurodegenerative health is influenced by a complex interplay of genetics, lifestyle, environment, and aging. If you are concerned about your cognitive health or family history, the most appropriate step is to consult with a qualified healthcare provider or a genetic counselor. They can help you interpret your overall health profile in the context of your personal history. Avoid making medical decisions based on single-variant reports, as these markers are only small pieces of a much larger and more complex biological puzzle.
How common is this variant?
The rs6733824 variant is common, with a minor allele frequency of approximately 0.45 across diverse continental ancestries.
Frequently asked questions
Is rs6733824 the same as the APOE4 Alzheimer's risk gene?
No, rs6733824 is a regulatory variant in the promoter region of the APOE gene, whereas APOE4 refers to a specific coding variant that changes the structure of the APOE protein. They are distinct genetic markers with different types of potential effects on gene function.
Can I use this SNP to predict my risk of Alzheimer's?
No, this SNP is not a diagnostic tool. Current evidence for its impact on disease risk is limited, and Alzheimer's disease is a complex condition influenced by many genetic and environmental factors.
What should I do if I have a specific genotype for this variant?
You do not need to take any specific action. Genetic variants like this are common and are not used for clinical decision-making. If you have concerns about your brain health, speak with your doctor about lifestyle factors and overall health screenings.
Does this variant affect how medications work?
There is no established evidence that rs6733824 affects medication response. Always discuss any concerns about your medications or dosing with your clinician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6733824?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in APOE
Variant in the APOE/TOMM40 locus associated with late-onset Alzheimer's disease risk.
Downstream variant in the APOE region associated with lipid metabolism profiles and healthspan indicators.
Variant (c.497G>A, p.Arg166Gln) in the APOE gene known as Apolipoprotein E4 Christchurch, which has been shown in clinical case studies to confer resistance to familial Alzheimer's disease pathology.
Defines the APOE ε2 allele, associated with lower LDL cholesterol and reduced risk of Alzheimer's disease.
Upstream regulatory variant influencing APOE transcription and plasma lipid modulation.
Variant in the APOE gene cluster strongly associated with low-density lipoprotein cholesterol levels and altered susceptibility to cardiovascular disease.